Recombinant antibody purification – methods, steps and challenges

The purification of recombinant antibodies is an indispensable step in the overall protein production, thus also essential for various aspects in therapy, diagnostics and research. Nevertheless, different antibody formats – be it full-length abs or antibody fragments – are valued for their distinctive antigen-binding properties respectively the ability to bind to one specific epitope, which is a great advantage over polyclonal antibodies and opens a wide range of different applications.

After their recombinant expression, recombinant antibodies are not immediately ready to use. Instead, they need to go further processing steps of recombinant antibody production – one of them being the purification of recombinant antibodies.

Key Takeaways

• The CHO Advantage: Unlike bacterial platforms that require disruptive cell lysis and complex refolding, mammalian CHO cells secrete properly folded, fully glycosylated recombinant antibodies directly into the culture supernatant, drastically streamlining the purification process.
• Critical Quality Attributes: High-quality downstream processing must ensure >95% purity and strictly minimized endotoxin levels (<1 EU/mg) to prevent false positives in in vitro assays and immunogenic responses in in vivo models.
• Complex Formats: Modern purification strategies must extend beyond standard Protein A affinity to accommodate bispecific antibodies and scFvs, utilizing specialized resins (e.g., KappaSelect, LambdaSelect) and Size Exclusion Chromatography (SEC) to clear inactive aggregates.
• High-Throughput Translation: For AI-designed libraries, automated high-throughput (HTP) purification workflows are essential to maintain rapid timelines from sequence to validated data.

Recombinant antibody purification – a definition

The definition of recombinant antibody purification refers to the process of isolating and separating a specific recombinant antibody from a complex mixture of other proteins, cellular debris, and impurities.

The goal of purification is to obtain a high yield of pure recombinant antibody, suitable for research, diagnostic, or therapeutic purposes.

Steps and methods in recombinant antibody purification

The purification workflow depends entirely on the chosen expression system. A major bottleneck in bacterial expression (e.g., E. coli) is the frequent accumulation of antibodies in insoluble inclusion bodies, requiring harsh cell lysis, denaturation, and complex refolding protocols. In contrast, advanced mammalian platforms utilizing CHO cells secrete fully folded and assembled antibodies directly into the culture medium.

For these mammalian systems, the initial recovery process bypasses cell lysis entirely, relying instead on gentle centrifugation and depth filtration to harvest the clarified supernatant, preserving the structural integrity and binding properties of the antibody.

Typically, target proteins are first designed to be affinity tagged to facilitate the purification process, allowing target proteins to maintain their properties without interacting directly with a matrix.

When developing a purification strategy, it is crucial to keep the end goal for the purified protein in mind. A popular purification method is affinity chromatography (or affinity purification), where the unrefined sample is made to flow through a column that is packed with protein A.

The technique is widely used to separate a biomolecule from a mixture by making use of a specific macromolecular binding interaction, which is determined by the biomolecule of interest, e. g. antibody and antigen, substrate and enzyme, ligand and receptor, or nucleic acid and protein.

Despite significant progress, physicochemical-based chromatographic methods such as size exclusion, ion exchange, and hydrophobic interaction are often required in addition to affinity tags.

Another method of protein tagging involves engineering an antigen peptide tag onto it, which can then be purified on a column or via incubation. The purified tagged proteins can be easily separated from other proteins and released into the elution buffer. To remove tags, a protease cleavage site can be added between the tag and the protein.

To monitor the progress and results of each purification step, SDS-PAGE can be used during the purification process. Despite the availability of alternative technologies, coomassie staining remains one of the most commonly used methods for visualizing protein bands on gels.

What is needed for recombinant antibody purification?

Establishing an optimal environment for recombinant antibody purification requires specialized equipment tailored to the expression host. For mammalian transient expression, disruptive lysis tools like French presses or ultrasonic homogenizers are entirely unnecessary and potentially detrimental to the target protein.

Instead, the initial harvest requires high-capacity centrifuges and depth filtration systems to clarify the cellular supernatant. Following clarification, automated liquid chromatography systems (such as ÄKTA platforms) operated at 4°C are essential.

The fundamental elements of a therapeutic-grade chromatography system comprise highly specific column matrices (e.g., modern Protein A, G, or L resins), precision gradient pumps, UV/visible detection systems for real-time peak monitoring, and automated fraction collectors. For high-throughput screening of AI-designed libraries, robotic liquid handling and automated parallel chromatography setups are required to purify hundreds of variants simultaneously without cross-contamination.

Recombinant antibody purification in context – rAB expression and other production steps

Recombinant antibody purification plays a crucial role in the production of antibodies, including full-length IgG1 antibodies, heavy-chain and single-chain antibodies (scFv), and antibody fragments like Fab. The initial recombinant antibody expression typically involves the use of bacterial expression systems (e.g. Escherichia coli) or mammalian cells such as HEK293 cells or CHO cells.

During the expression phase, codon optimization is often employed to enhance protein production, and characterization assays are conducted to validate the functionality and specificity of the immunoglobulins (IgG antibodies). The choice of host cells, whether bacterial or mammalian cells, depends on the desired glycosylation patterns and protein folding requirements.

In certain cases, antibody production may involve hybridoma technology or phage display methodologies, leading to the generation of mAbs (monoclonal antibodies). Regardless of the production approach, it is essential to monitor protein concentration and remove impurities, including endotoxin, to ensure the final product’s quality.

The recombinant antibody purification process often includes the use of affinity tags, such as the Fc domain or antigen peptide tags, to facilitate efficient purification. By utilizing these tags, the target antibodies can be isolated from the complex mixture of cellular components and reagents.

Facing challenges in recombinant protein expression and purification

Recombinant protein expression and purification comes with several challenges in practice. The accumulation of the product within the cell can trigger stress responses that impede cell growth. The buildup of insoluble and biologically inactive aggregates (inclusion bodies) reduces the production yield, especially when attempting to obtain high molecular weight, multi-domain, or membrane proteins.

Additionally, recombinant protein expression requires meticulous planning and process optimization to determine the appropriate host, culture conditions, duration, and purification strategy.​^​1​

Recombinant antibody expression and purification at evitria

As a specialized strategic partner, evitria brings the technical authority of over 140,000 completed transfections and more than 25,000 uniquely expressed antibodies. Operating exclusively within an optimized CHO cell platform, we bridge the gap between early-stage discovery and pre-clinical scale-up. Our downstream processing is engineered to eliminate the bottlenecks typically associated with complex formats, delivering antibodies with guaranteed >95% purity and stringent endotoxin controls (<1 EU/mg).

Our dedicated downstream processing capabilities include:

• High-throughput (HTP) automated purification for rapid validation of AI-designed libraries.
• Standard affinity chromatography (Protein A) alongside advanced alternative resins.
• Specialized affinity matrices (e.g., KappaSelect, LambdaSelect, and Protein L) specifically tailored for complex bispecific antibodies and customized scFv-Fc fusions.
• Preparative Size Exclusion Chromatography (SEC) for the rigorous depletion of high-molecular-weight aggregates and target validation.

Overcoming purification bottlenecks in bispecific antibodies

The rise of bispecific antibodies has introduced significant downstream challenges, notably the mispairing of light chains and the formation of homodimers. Standard Protein A chromatography is often insufficient to separate the desired heterodimer from closely related mispaired byproducts. Overcoming this requires an optimized, multi-step purification strategy.

By sequentially combining customized affinity capture (such as utilizing CH1 or specialized light-chain specific resins) with polishing steps like SEC or Ion Exchange (IEX) chromatography, researchers can successfully isolate the correct bispecific format, ensuring the functional activity required for complex therapeutic applications.

FAQs about expression and purification of recombinant antibodies

What does the production process of recombinant antibodies look like?

Recombinant antibodies are synthesized in vitro by incorporating the heavy and light chains of the antibody into an expression vector. Following expression, they are usually isolated from periplasmic fractions or the culture supernatant.

What are recombinant proteins?

Recombinant proteins are often considered as high-tech products in biotechnology and require know-how across many disciplines such as cell biology, biochemistry, and molecular biology. They can be defined as long chains of condensed amino acids, produced by host cells.

These were reprogrammed to transcribe recombinant DNA sequences, which is the template for messenger RNA. Recombinant proteins can be designed to possess unique properties, which are not found in natural proteins. This includes synthetic enzyme for drug discovery, recombinant monoclonal antibodies, and therapeutic fusion proteins.

The solubility of recombinant proteins determines their quality; however, even a soluble protein can be limited in its ability to exhibit functional activity as it may contain non-functional, misfolded, or soluble aggregates.​^​2​

How are recombinant proteins produced?

1. Identifying a sequence source for the protein of interest
2. Physically combining DNA molecules from multiple sources through cloning, ligation, or reverse transcription of nucleic acids
3. Generating DNA vectors by incorporating appropriate promoter, plasmid: Either through techniques from molecular biology to combine genetic material obtained from various natural sources, or by producing recombinant DNA entirely in vitro using the technique of gene synthesis. This involves creating overlapping single stranded DNA fragments, followed by heating, annealing, ligation, and amplification with PCR, allowing site-specific mutation of residues.
4. Transformation/transfection
5. Executing protein synthesis in cell cultures: bacteria E. coli for simple proteins (peptides) and eukaryotic host cells (e.g. mammalian CHO cell lines) for complex proteins
6. Downstream processing: isolation of proteins of interest

What is SDS-PAGE?

SDS-PAGE stands for sodium dodecyl sulfate – polyacrylamide gel electrophoresis and is often used for separating proteins with molecular masses ranging from 5 to 250 kDa. By using a combination of polyacrylamide gel and sodium dodecyl sulfate (SDS), the influence of structure and charge can be eliminated, allowing proteins to be separated based solely on their molecular weight differences.

Sources